Drug intelligence / Profile preview

lacticaseibacillus paracasei K56

Development stage
Preclinical
Lead developer
Yili
Modality
Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration
Oral
01

Overview

Lacticaseibacillus paracasei K56 is a novel probiotic strain isolated from the intestine of a healthy child, being developed by Inner Mongolia Yili Industrial Group. [7, 10, 11, 14] It is under investigation for its potential benefits in obesity and psychological stress. [2, 9] The proposed mechanism of action involves modulating the gut microbiota to create a more favorable composition for health. [2, 3, 9] In a human pilot study involving obese adults, daily supplementation with K56 at a dose of 2 × 10^9 CFU for 60 days led to significant reductions in percent body fat, visceral fat area, total body fat mass, waist circumference, and glycosylated hemoglobin compared to baseline. [2, 15] Animal studies have also shown that L. paracasei K56 can attenuate high-fat diet-induced obesity, reduce fat accumulation, and alleviate insulin resistance. [3] Another study in students suggested that K56 supplementation may alleviate stress and anxiety, possibly through the gut-brain axis by altering microbial composition and increasing metabolites like butyric acid. [9, 11] The strain has been incorporated into a commercial ambient fermented lactobacillus drink called Changyi 100%. [7]

Brand names
Changyi 100%
Other names
L. paracasei K56Lactobacillus paracasei subsp. paracasei K56

Beyond the preview

Go deeper on lacticaseibacillus paracasei K56.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on lacticaseibacillus paracasei K56.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call